Relmada Therapeutics (RLMD) Misses Q1 EPS by 21c

Relmada Therapeutics (NASDAQ: RLMD) reported Q1 EPS of ($0.58), $0.21 worse than the analyst estimate of ($0.37).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• Tesla readies August launch of CyberCab - The Information
• Micron Technology (MU) call put ratio 1.4 calls to 1 put on 1.2M contracts as share price up 4%
• Kaiser Aluminum names Fred Stephan as CEO, effective November 2026